MedTrace Logo

Dapivirine Gel Rectal Safety and PK Study

NCT03044379 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-02-08

No results posted yet for this study

Summary

Dapivirine Gel Rectal Safety and PK Study

Conditions

  • HIV 1 Infection

Interventions

DRUG

Dapivirine gel (0.05%)

MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.

OTHER

Universal HEC placebo gel

Sponsors & Collaborators

  • International Partnership for Microbicides, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-29
Primary Completion
2017-09-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044379 on ClinicalTrials.gov